Duorui pharmaceutical: it plans to invest 5.6 million yuan to establish a holding subsidiary, hairuidi pharmaceutical

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Unpacking China | Key Chinese Firms to Watch This Week （26/07/2026-01/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

CFMOTO’s Overseas Revenue More Than Quintuples in Five Years, Reaching 70% of 2025 Sales

Zhejiang CFMOTO Power Co., Ltd.（浙江春风动力股份有限公司）, the Hangzhou-based powersports manufacturer behind the CFMOTO brand, generated CNY 13.79 billion in overseas revenue in 2025, accounting for 69.8% of its total sales. The figure was up 27.6% from a year earlier and more than five times the CNY 2.555 billion the company recorded in overseas sales in 2020.

Himalaya Turns to Hong Kong for IPO

On September 14, after withdrawing the IPO application on US SEC, China's online audio platform Himalaya submitted an IPO prospectus to the Hong Kong Stock Exchange. The underwriters are Goldman Sachs, Morgan Stanley and CICC.